Skip to main
BDSX
BDSX logo

Biodesix (BDSX) Stock Forecast & Price Target

Biodesix (BDSX) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Biodesix Inc. is anticipated to achieve robust financial performance, with projected revenue growth of 30% for 2026, driven primarily by a 32% increase in Lung Diagnostic Testing revenue. The company has demonstrated strong operational discipline and is well-capitalized, positioning it effectively to realize its expansion goals. Additionally, as the company plans to expand its sales force to approximately 120 representatives by the end of 2026, it is positioned to enhance its market reach and drive future revenue growth.

Bears say

Biodesix Inc. reported a revenue miss for the first quarter of 2025 and subsequently lowered its revenue guidance for the full year, primarily due to a shift in its commercial strategy. This strategic pivot indicates potential operational challenges and uncertainty regarding future revenue streams. Given these developments, the financial outlook appears concerning as reliance on contract-based services may expose the company to fluctuations in demand and revenue stability.

Biodesix (BDSX) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biodesix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biodesix (BDSX) Forecast

Analysts have given Biodesix (BDSX) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Biodesix (BDSX) has a Strong Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biodesix (BDSX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.